Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma.
Xiaolin PengYao LiuShan ZhuXin PengHui LiWenhui JiaoPeng LinZhe ZhangYuling QiuMeihua JinRan WangDexin KongPublished in: Journal of cancer research and clinical oncology (2019)
Dual inhibition of PI3K/Akt and MAPK/ERK pathway by GDC-0980 and Refametinib might be a promising treatment strategy for HSCC patients.